Skip to main content
. 2020 Aug 20;5(16):e137792. doi: 10.1172/jci.insight.137792

Figure 7. Meta-analysis of serious adverse (≥ grade 3) fluid-electrolyte abnormalities and blood pressure in subjects on placebo or standard therapy versus those on HDACi.

Figure 7

Forest plots of the OR with horizontal lines representing 95% CI and diamonds representing OR for all studies combined. There is a significant increase in odds of (A) any fluid-electrolyte abnormality (P < 0.0001), (B) hyponatremia (P = 0.0003) or (C) hypokalemia (P < 0.0001) or (D) a change in blood pressure (either increase or decrease, P = 0.015) with HDACi use.